MPG.eBooks - Search Results - "Cost-benefit Analysis"

Search alternatives:
"Cost-benefit Analysis" » "Cost-benefits Analysis"

Cover Image

1

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Cover Image

2

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Cover Image

3

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Cover Image

4

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Cover Image

5

CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) : indication : coronary artery disease with or without peripheral artery disease

Published 2018

CADTH

Subjects: “...Cost-Benefit Analysis...”

Cover Image

6

CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) : indication : coronary artery disease with or without peripheral artery disease

Published 2018

CADTH

Subjects: “...Cost-Benefit Analysis...”